Summary.-Eleven patients with measurable subcutaneous or pulmonary metastases were selected for a study of the effectiveness of the radiosensitizer misonidazole (MIS). Evaluable 
growth-delay studies indicated enhancement ratios ranging from 1-1 to >1-5. An enhancement ratio of 1-3 was measured in a case of squamous carcinoma treated by a 10-fraction course of irradiation. Evidence of sensitization was obtained in breast carcinoma, osteosarcoma, leiomyosarcoma, prostatic carcinoma and synoviosarcoma. The results of this study support the view that MIS may improve the radiotherapeutic management of a wide range of tumours, although more extensive data are required to identify those categories of disease in which greatest benefit will be obtained, and to indicate the optimum radiation schedule.
ALTHOUGH animal experiments have shown that misonidazole (MIS) is an effective sensitizer of hypoxic cells, and that its use improves the local cure rate of a wide range of experimental tumours (Denekamp & Fowler, 1978) (Thomlinson et al., 1976; Dawes et al., 1978) . In the study by Thomlinson and The dose-response data in Case 3 were unusual in demonstrating a large difference between 400 and 500 rad after MIS.
The other 2 cases, however, appear to resolve differences of 200 rad between treatments, and indicate that it is possible to use the method for such comparison.
In previously reported studies of MIS in man, large single doses of radiation (800-1200 rad) have been used (Thomlinson et al., 1976; may not be necessary to use large fractions of irradiation to achieve radiosensitization in man.
Other animal experiments have shown that when radiosensitizers are given with fractionated radiation, the sensitizing enhancement ratio falls considerably (Hill & Bush, 1978) . This has led to the postulate that re-oxygenation occurred between radiation treatments, thus reducing the number of hypoxic cells. The majority of these experiments have, however, used animal tumours that re-oxygenate rapidly.
When the same experiments were repeated with a tumour that re-oxygenates poorly (Sheldon & Fowler, 1978) (Watson et al., 1978) , which showed a benefit for hyperbaricO2 even in patients treated with 30 fractions of radiation. The evidence encourages the study of MIS with multifraction regimes in other human tumours.
The use of internal controls in sen.8''itizer studies means that all metastatic tumour is exposed to MIS, with some tumour irradiated before and some after the drug. Experimental work has shown, both in vitro (Stratford & Adams, 1978) and in vivo (Brown et al., 1978; Pedersen et al., 1978) 
